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Ambulatory Care Survey, National Hospital Discharge Survey
etc.) in terms of data elements’ design, efﬁciency of a hierarchi-
cal structure and data integrity, data security, etc. Comparative
analysis has been conducted using a tool that aggregates ques-
tions on qualitative registries’ metrics. RESULTS: Compared to
other registries, NVDRS has a well-deﬁned goal, sufﬁcient for the
development of a PH registry (to assist the design of PH inter-
ventions for a reduction of mortality due to violent deaths).
NVDRS is a population based, conﬁdential, incident-driven, com-
puterized information system. NVDRS represents a new genera-
tion of systems with the highest level of data complexity because
of the aggregation of multiple data sources obtained from differ-
ent state agencies. NVDRS encompasses essential registry func-
tions and attributes sufﬁcient to accomplish the system’s major
goals. It has well deﬁned core elements, which allows for many
types of analysis. CONCLUSIONS: A comparative analysis of
NVDRS demonstrates that goals, design and structure of this
system promote best practices for the PH patient registries.
PMC11
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OBJECTIVES: To develop a Markov model that can be cali-
brated to different countries; to facilitate country-speciﬁc eco-
nomic evaluations of a vaccine that protects against infection
with multiple human papillomavirus (HPV) types. METHODS:
We developed an Excel-based Markov model of the natural
history of HPV and cervical cancer using a cycle length of six
months for transitioning between health states (Normal, HPV,
Cervical Intraepithelial Neoplasia (CIN) 1, CIN 2, CIN 3, Cer-
vical Cancer (Stages 1 to 4), and death. Health states are strati-
ﬁed by HPV type (16, 18, 31, 45, 52, Other Oncogenic, and
Non-oncogenic). Using a lifetime simulation of 12-year old girls,
the model was calibrated to current data for two European 
countries (The Netherlands, UK (UK)). Calibration endpoints
included: 1)Age-speciﬁc HPV prevalence; 2)HPV type distribu-
tion in cervical disease; 3)Prevalence of pre-cancerous lesions;
and 4)Age-speciﬁc cervical cancer incidence and mortality.
Observed screening practices and coverage (three-yearly for UK,
ﬁve-yearly for The Netherlands) were used for calibrating to a
screened environment. Transition probabilities were varied,
within established ranges, to reproduce calibration endpoints.
RESULTS: Model-predicted outcomes correlated well with
observed data for both UK and The Netherlands. Overall, HPV
prevalence was comparable for UK (model-predicted = 7.1%;
observed = 9.6%) and The Netherlands (model-predicted =
6.4%; observed = 9.2%). Differences between countries were
observed in other endpoints, such as crude cervical cancer inci-
dence per 100,000 (UK: model-predicted = 10.4, observed =
10.2; The Netherlands: model-predicted = 8.5, observed = 8.1),
as well as cervical cancer mortality per 100,000 (UK: model-
predicted = 5.2, observed = 5.1; The Netherlands: model-
predicted = 2.8, observed = 2.9). CONCLUSIONS: A model of
the natural history of HPV and cervical cancer was successfully
calibrated to two countries. It is important to calibrate to several
epidemiological endpoints in countries so that health economic
beneﬁts of vaccine can be accurately projected in future 
cost-effectiveness analyses.
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OBJECTIVES: To conduct a structured review of the literature
to identify cost-effectiveness evaluations involving at least one 
of four biologic treatments: adalimumab, anakinra, etanercept
and inﬂiximab for the treatment of autoimmune disorders.
METHODS: A structured review of the literature was conducted
in EMBASE and PubMed from January 1995 to February 2005
to identify all relevant cost-effectiveness evaluations investigat-
ing one or more of these four treatments in autoimmune 
disorders. RESULTS: Fifteen full economic evaluations were
identiﬁed. There were 12 for rheumatoid arthritis, 2 for Crohn’s
disease, and 1 for ankylosing spondylitis. There were 5 studies
in the UK, 4 in the United States, 2 studies in Sweden, one joint
study in Sweden and in the UK, one study in France, one study
in The Netherlands and one study in Spain. The majority of eval-
uations used modeling to project the long-term cost-effectiveness
of treatments. In general, cost-effectiveness ratios were favorable
for the treatment of patients with refractory disease not respond-
ing to previous treatments whether in rheumatoid arthritis or
ankylosing spondylitis. In Crohn’s disease, biologic treatments
were not cost-effective in the treatment of perianal ﬁstulae, or
for maintenance therapy in patients with moderate to severe
active disease. Due to the high cost of these treatments, cost-
effectiveness ratios were less favorable for maintenance therapy
across diseases. CONCLUSION: Modeling the cost-effectiveness
of more expensive biologic treatments in autoimmune disorders
presents signiﬁcant challenges due to the chronic and recurring
nature of diseases such as rheumatoid arthritis, Crohn’s disease
and ankylosing spondylitis. A better understanding of these
issues will be useful to researchers developing future models for
these disease areas but also for other autoimmune disorders for
which biologic agents may be appropriate such as, for example,
ulcerative colitis, psoriasis and psoriatic arthritis.
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OBJECTIVES: To investigate factors inﬂuencing health prefer-
ence with expectancy-value model (EVM). METHODS: EVM, a
model widely used to explore underlying factors of attitudes was
applied to study health preference, which was categorized as atti-
tude in psychology. The factors include attitudinal attributes
(AAs) and external variables. AAs are measured in a sum of mul-
tiplications of one’s subjective probability (expectancy) and per-
ceived value of attributes. In one-to-one interviews, four AAs
identiﬁed in focus group discussion, namely, reduction in quality
of life (RQoL), burden to family (BTF), dependence on others
(DOO) and inability to work (ITW) were assessed using 7-point
Likert scales to measure expectancy and value of each attribute.
Health preference was measured using visual analogue scales
(VAS, range 0–100). Univariate analyses were used to identify
external variables (age, gender, ethnicity, education, housing,
marital status, and concurrent chronic diseases) that cause 
signiﬁcant difference in VAS. Multiple linear regression model
(MLR) was used to investigate the explanative power of AAs and
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possible signiﬁcant external variable(s) separately or in combi-
nation. RESULTS: Twenty-ﬁve Chinese and 21 Indians (mean
(SD) age: 45.0 (15.55) years, 55.6% female) were interviewed.
Ethnicity was identiﬁed as the only independent variable causing
signiﬁcant difference in VAS (p < 0.05). RQoL, BTF, DOO, ITW
were found to explain the variation of VAS of 26.5%, 27.2%,
23.2%, 17.1% respectively in separate MLR models (p < 0.05).
Combining ethnicity together with the sum of AAs explained up
to 27.3% of the variation in VAS, while a model with ethnicity
alone only accounted for 10.7% (p < 0.05). When MLR was
done to examine different predicting power of AAs by ethnicity,
ITW failed to predict VAS of Indians (0.3%, p = 0.80) while the
other 3 AAs moderately explained from 9.1% to 22.9% of the
variation p < 0.05). CONCLUSIONS: EVM may be helpful in
explaining the variations in health preference and predicting
important factors.
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OBJECTIVES: Great debate exists over appropriate cost/QALY
thresholds. We assessed reporting of cost-effectiveness thresholds
in the literature to examine prevailing judgements about society’s
willingness-to-pay per QALY. We hypothesized that stated
thresholds were directly related to an author’s home country
GDP per capita and that they have increased over time to reﬂect
economic growth. METHODS: We evaluated 573 cost-
effectiveness analyses (CEAs) published between 1998–2003 and
listed in the Tufts-NEMC CEA registry. We scrutinized authors’
judgments regarding appropriate cost/QALY thresholds (e.g.,
that an incremental cost/QALY ratio under $50,000/QALY rep-
resents “good value for money”), and examined whether thresh-
olds differed by author’s home country GDP per capita (2000
values). RESULTS: CEAs most frequently originated from the US
(n = 320), UK (n = 68), Canada (n = 45), and The Netherlands
(n = 35). Of 573 studies, 325 CEAs (57%) stated an explicit
threshold. The most frequent thresholds used in the US were
$50,000/QALY (52%), followed by the classiﬁcation pro-
posed by Laupacis (CAN$20,000–CAN$100,000) (16%), and
$100,000/QALY (11%). Most Canadian studies (65%) used the
Laupacis classiﬁcation, and most UK studies (52%) used
GBP30,000/QALY. The prevailing US threshold ($50,000/
QALY) corresponded to approximately 1.4 times US GDP per
capita, whereas the UK threshold (GBP30,000/QALY) was
approximately 1.9 times UK GDP per capita. The lower and
upper limits of the Laupacis classiﬁcation used in Canada cor-
responded to 0.6 to 2.9 times Canadian GDP per capita. Thresh-
olds used by authors have not changed signiﬁcantly over time
and where not inﬂated to address inﬂation or economic growth.
CONCLUSIONS: Thresholds used in the US, UK, and Canada
do not appear to be related to GDP per capita, and have not
increased over time. More research is needed to determine appro-
priate country-speciﬁc or disease-speciﬁc thresholds. Mecha-
nisms for updating thresholds to reﬂect inﬂation rates or changes
in GDP are warranted.
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OBJECTIVES: The primary objective of this study was to deter-
mine the feasibility of an internet-based method for eliciting 
population based preferences for generic health states using the
standard gamble procedure. METHODS: An internet-based
standard gamble utilizing a chance board and a “ping-pong”
search procedure was introduced to twenty-ﬁve respondents who
were primarily recruited via e-mail solicitation. The respondents
were asked to elicit their preference for an EQ-5D generic health
state (21221). The same set of respondents were asked to elicit
their preference for their current health state using a internet-
based visual analog scale. RESULTS: Fifty-eight percent of the
25 respondents were male. Eighty percent of the respondents
were either health care professionals or academic-based health
service researchers, and the remainder were from the general
population. The majority of the respondents were White. Four
respondents were Hispanic and one was Asian. The mean age of
the respondents was 39.7 years. Both the standard gamble and
visual analog scale elicitation results were normally distributed
(Kolmogorov-Smirnov, p > 0.05). The mean elicited preference
for the generic health state using standard gamble was 0.8726
(s.d. 0.095), and the mean visual analog scale elicited preference
for the respondents’ current health state was 0.8721 (s.d. 0.088).
CONCLUSION: An internet-based approach for eliciting pref-
erence for a generic health state using a sophiticated standard
gamble procedure appears to be an efﬁcient means for perform-
ing such inquiry.
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OBJECTIVE: The objective of this study was to analyze the rela-
tionship between general health status and patient satisfaction
by conducting a meta-analysis on two previously conducted
studies. METHODS: Data collected from two cross-sectional
studies performed in 1997 and 2001 were pooled. Data collected
in 1997 was obtained from 737 patients taking a Selective Sero-
tonin Reuptake Inhibitor selected randomly from a prescription
claims database of a managed care company in Utah. Data col-
lected in 2001 was obtained randomly from 443 patients ﬁlling
prescriptions at 10 pharmacies located in the Houston, Texas.
General health status was measured using the SF-12 scale.
Patient satisfaction with the services provided by the health plan
was measured using an eight item scale. The satisfaction scale
across the two data sets was standardized to a 0–100 scale,
where a score of 100 was considered highly satisﬁed. Data were
coded and analyzed to report descriptive and correlation analy-
ses. RESULTS: The pooled dataset resulted in 1180 observations.
The mean age of the respondents was 47.02 ± 11.41 years (range
10 to 82) of which majority were females (72.6%). Data showed
that the respondents had low physical composite scores (PCS)
(48.34 ± 10.08) and mental composite scores (MCS) (46.39 ±
11.04) on the SF-12 scale. The mean patient satisfaction score
was 71.18 (± 17.89). Correlation analysis indicated there was no
association of either the PCS or the MCS with overall patient
satisfaction scores (p > 0.05). However, there was a positive asso-
ciation of individual items like health coverage provided by the
plan and out of pocket expenses paid by patient for health 
